Wall Street Zen Upgrades TuHURA Biosciences (NASDAQ:HURA) to Hold

TuHURA Biosciences (NASDAQ:HURA) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Monday.

A number of other research firms have also recently commented on HURA. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of TuHURA Biosciences in a research report on Tuesday, February 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, TuHURA Biosciences has an average rating of “Hold” and an average target price of $9.00.

TuHURA Biosciences Price Performance

Shares of HURA opened at $1.81 on Monday. TuHURA Biosciences has a 1-year low of $0.41 and a 1-year high of $4.44. The stock has a market cap of $109.90 million, a PE ratio of -3.62 and a beta of -0.33. The firm has a fifty day moving average price of $1.30 and a 200 day moving average price of $1.65.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new stake in TuHURA Biosciences in the third quarter valued at about $26,000. JPMorgan Chase & Co. purchased a new position in shares of TuHURA Biosciences during the 2nd quarter worth approximately $27,000. Intech Investment Management LLC purchased a new position in shares of TuHURA Biosciences during the 2nd quarter worth approximately $29,000. Invesco Ltd. acquired a new stake in shares of TuHURA Biosciences in the 2nd quarter valued at approximately $30,000. Finally, Merck & Co. Inc. acquired a new stake in shares of TuHURA Biosciences in the 2nd quarter valued at approximately $31,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.